BiotechTube

MK-3475 + ASG-22CE

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bladder Cancer

Conditions

Bladder Cancer

Trial Timeline

Oct 1, 2023 → Sep 30, 2027

NCT ID
NCT05879653

About MK-3475 + ASG-22CE

MK-3475 + ASG-22CE is a phase 2 stage product being developed by Astellas Pharma for Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05879653. Target conditions include Bladder Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Bladder Cancer were approved

Approved (20) Terminated (1) Active (0)
✅mirabegron + solifenacinAstellas PharmaApproved
✅Mirabegron + PlaceboAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
✅Mirabegron + Tolterodine ERAstellas PharmaApproved
✅Alpha blocker + placebo + solifenacinAstellas PharmaApproved
✅Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05879653Phase 2Recruiting

Competing Products

20 competing products in Bladder Cancer

See all competitors
ProductCompanyStageHype Score
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
EG-70 (phase 1) + EG-70 (phase 2)enGenePhase 1/2
29
mirabegron + solifenacinAstellas PharmaApproved
43
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Enfortumab vedotinAstellas PharmaPhase 1
21
Mirabegron + PlaceboAstellas PharmaApproved
43
SolifenacinAstellas PharmaApproved
43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
40
solifenacin succinateAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
BetanisAstellas PharmaPre-clinical
26
SolifenacinAstellas PharmaApproved
43
SolifenacinAstellas PharmaPhase 2
35
Mirabegron + Tolterodine ERAstellas PharmaApproved
43
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
26
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
43
warfarin + YM178Astellas PharmaPhase 1
29
Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + CisplatinAstellas PharmaPhase 3
40